TY - JOUR
T1 - The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma
AU - Takamori, Shinkichi
AU - Toyokawa, Gouji
AU - Taguchi, Kenichi
AU - Edagawa, Makoto
AU - Shimamatsu, Shinichiro
AU - Toyozawa, Ryo
AU - Nosaki, Kaname
AU - Seto, Takashi
AU - Hirai, Fumihiko
AU - Yamaguchi, Masafumi
AU - Shoji, Fumihiro
AU - Okamoto, Tatsuro
AU - Takenoyama, Mitsuhiro
AU - Ichinose, Yukito
PY - 2017/7
Y1 - 2017/7
N2 - The aim of this study was to clarify the clinical significance of the Controlling Nutritional Status (CONUT) in malignant pleural mesothelioma. The data of 83 patients were analyzed. The high CONUT group had significantly poorer overall survival (P < .001) and disease- or progression-free survival (P < .001). The CONUT score provides useful information for selecting patients who will benefit from the treatment. Introduction Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such treatment. Although the Controlling Nutritional Status (CONUT) score has been used to predict the prognosis in other types of malignancy, its utility in patients with MPM is unknown. The aim of this study was to clarify the clinical significance of the CONUT in patients with MPM. Methods The data of 83 patients, who were treated with surgery, chemotherapy, or multidisciplinary therapy, were analyzed in the present study. A cut-off CONUT score of 2 was used to classify all of the patients into low or high CONUT groups. Results Fifty-two of the 83 patients were classified into the low CONUT group. A high CONUT score was significantly correlated with chemotherapy alone (P = .011). The high CONUT group had significantly poorer overall survival (OS) (P < .001) and disease- or progression-free survival (DFS/PFS) (P < .001). The clinical stage and the CONUT score were found to be independent predictive factors for the OS: clinical stage, I/II and III/IV; P = .001 and CONUT score, ≥ 3 and ≤ 2; P = .011, respectively. The clinical stage and the CONUT score were also independent predictive factors for DFS/PFS: clinical stage, I/II and III/IV; P = .006 and CONUT score, ≥ 3 and ≤ 2; P = .013, respectively. Conclusions The CONUT score was an independent predictor of a poor prognosis in the patients with MPM. This score provides useful information for selecting patients who will benefit from the treatment.
AB - The aim of this study was to clarify the clinical significance of the Controlling Nutritional Status (CONUT) in malignant pleural mesothelioma. The data of 83 patients were analyzed. The high CONUT group had significantly poorer overall survival (P < .001) and disease- or progression-free survival (P < .001). The CONUT score provides useful information for selecting patients who will benefit from the treatment. Introduction Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such treatment. Although the Controlling Nutritional Status (CONUT) score has been used to predict the prognosis in other types of malignancy, its utility in patients with MPM is unknown. The aim of this study was to clarify the clinical significance of the CONUT in patients with MPM. Methods The data of 83 patients, who were treated with surgery, chemotherapy, or multidisciplinary therapy, were analyzed in the present study. A cut-off CONUT score of 2 was used to classify all of the patients into low or high CONUT groups. Results Fifty-two of the 83 patients were classified into the low CONUT group. A high CONUT score was significantly correlated with chemotherapy alone (P = .011). The high CONUT group had significantly poorer overall survival (OS) (P < .001) and disease- or progression-free survival (DFS/PFS) (P < .001). The clinical stage and the CONUT score were found to be independent predictive factors for the OS: clinical stage, I/II and III/IV; P = .001 and CONUT score, ≥ 3 and ≤ 2; P = .011, respectively. The clinical stage and the CONUT score were also independent predictive factors for DFS/PFS: clinical stage, I/II and III/IV; P = .006 and CONUT score, ≥ 3 and ≤ 2; P = .013, respectively. Conclusions The CONUT score was an independent predictor of a poor prognosis in the patients with MPM. This score provides useful information for selecting patients who will benefit from the treatment.
UR - http://www.scopus.com/inward/record.url?scp=85014198986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014198986&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2017.01.008
DO - 10.1016/j.cllc.2017.01.008
M3 - Article
C2 - 28274690
AN - SCOPUS:85014198986
SN - 1525-7304
VL - 18
SP - e303-e313
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 4
ER -
